We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Secukinumab 300 mg administered with an auto-injector ...
Secukinumab achieved complete symptom resolution in patients with pediatric generalized pustular psoriasis (GPP) by week 2, with sustained improvements through week 70. The treatment regimen was ...
More patients with recently diagnosed psoriatic arthritis (PsA) saw clinical improvement by 3 months in a treat-to-target strategy with secukinumab, a monoclonal antibody targeting interleukin-17, ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. SAN DIEGO — An intravenous formulation of secukinumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback